SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4550)6/24/1998 9:13:00 PM
From: Robert L. Ray  Read Replies (2) | Respond to of 6136
 
To All,

Don't really know how usefull this info will be or if it's been posted yet but I accidentally ran across a good link on AG3340 so I thought I'd post it. It has some pretty detailed info on the AG3340 rat preclinicals but not so much on the AG3340 phase 1 trials. slip.net



To: scaram(o)uche who wrote (4550)6/24/1998 11:04:00 PM
From: Peter Singleton  Read Replies (2) | Respond to of 6136
 
Rick, you said

<<Arrrrrggggghhhhhh...... all those words, and no expansion on the key
phrase, "three important viral markers". One of them is presumably a
gp120 epitope, which would not be positive news for AGPH.>>

naive question, but why would a gp120 epitope in this case be not such good news for AGPH?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News